Abstract: The present invention relates to a herpes zoster vaccine composition, which comprises glycoprotein E of Varicella zoster virus, a glucopyranosyl lipid adjuvant, and a metabolic oil, and selectively increases a cell-mediated immune reaction without having disadvantages of attenuated live vaccines, thereby exhibit high safety and a high preventive effect against herpes zoster.
Type:
Grant
Filed:
December 20, 2017
Date of Patent:
March 9, 2021
Assignees:
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, INFECTIOUS DISEASE RESEARCH INSTITUTE
Inventors:
Hyo Jung Nam, Eun Mi Kim, Duck Hyang Shin, Steven G. Reed, Kang Il Yoo, Sung Jun Hong
Abstract: Provided is a carboxymethyl cellulose or a salt thereof, in which when the carboxymethyl cellulose or the salt thereof is used as a binding agent for an electrode of a nonaqueous electrolyte secondary battery, defects, such as pinholes, on a surface of the electrode are reduced and a battery including the electrode has a good capacity retention. A method for producing a carboxymethyl cellulose or a salt thereof includes an alkali cellulose formation step (step 1) of allowing cellulose and an alkali to react with each other in the presence of a mixed solvent containing water and an organic solvent, an etherification step (step 2) of allowing the resulting alkali cellulose and an etherifying agent to react with each other, a purification step (step 3) of washing and drying the resulting reaction mixture, and a pulverization step (step 4) of pulverizing the resulting purified product.
Abstract: The present invention relates to determining the carrier status of Annexin A5 M2 haplotype of parents (both male and female) prior to and/or after pregnancy to minimize the risk of pregnancy complications, including, but not limited to, recurrent pregnancy loss (RPL), infertility, miscarriage, in vitro fertilization (IVF) failure, IUI failure, implantation failure, foetal growth restriction (FGR), small for gestational age (SGA) newborn, intra-uterine foetal death (IUFD), gestational hypertension (GH), pre-eclampsia (PE) and/or venous thromboembolism (VTE). Once M2 carrier status is determined, methods of intervention, including administration of low molecular weight heparin (LMWH) and/or other anti-coagulants can be administered either prior to and/or after pregnancy. Methods of detecting the carrier status as well as method of diagnosing and or predicting prognosis based on the M2 carrier status of a patient and/or couple is also contemplated.
Abstract: The present invention relates to an immune modulator having a novel structure, and an immunologic adjuvant composition containing the same and, more specifically, to an modulator, which is a lipopolysaccharide (LPS) analog having reduced toxicity, and a use thereof. The immune modulator of the present invention exhibits immune enhancement effects by having excellent innate immunity and ability to induce an adaptive immune response to a specific pathogen, and is very safe by having low toxicity. In addition, a vaccine containing the immune modulator of the present invention contains both an immune modulator and an alum, thereby improving immune enhancement effects compared with when using only the immune modulator.
Type:
Grant
Filed:
October 30, 2017
Date of Patent:
February 16, 2021
Assignee:
EYEGENE INC.
Inventors:
Yang Je Cho, Kwangsung Kim, Na Gyong Lee, Shin Ae Park
Abstract: The present invention describes a method for preparing a polymannan extract from freeze-dried aloe powder. The polymannan extract of the present invention is further used to formulate a sterile injectable formulation for the treatment of one or more cancers, leukemias and lymphomas, prostate cancer, breast cancer, and colon cancer, immune diseases, particularly immune related neoplasms, acquired immune deficiency syndrome, and hepatitis C.
Abstract: An object of the invention is to provide a method of uniformly and efficiently producing a saccharide having a sulfate group and/or a phosphate group in the molecule, or a compound containing the saccharide. [Solution] The present invention provides a method of producing a saccharide having a sulfate group and/or a phosphate group. The method comprises (a) a step of preparing a “first saccharide having a non-protected sulfate group and/or a non-protected phosphate group” and a “second saccharide having a non-protected sulfate group and/or a non-protected phosphate group” and (b) a step of condensing the first saccharide and the second saccharide prepared in the step (a) with each other.
Abstract: A method for producing a crosslinked gel. The method comprises steps of: (a) combining (i) water, (ii) alginic acid, alginates, or mixtures thereof, (iii) carboxymethylcellulose, (iv) a salt of calcium, magnesium or zinc, (v) a nonionic surfactant and (vi) fragrance to form a gel having a surface; and (b) contacting with the surface of said gel an additional aqueous solution of a salt of calcium, magnesium or zinc.
Type:
Grant
Filed:
March 29, 2017
Date of Patent:
January 26, 2021
Assignees:
Rohm and Haas Company, Union Carbide Corporation
Inventors:
Andrea C. Keenan, Emmett M. Partain, III, Theodore Tysak, Jennifer J. Todd
Abstract: A method of preparing a hydrogel product including crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include residual amine groups; and ii) acylating residual amine groups of the crosslinked glycosaminoglycans provided in i) to form acylated crosslinked glycosaminoglycans.
Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
Type:
Grant
Filed:
July 9, 2017
Date of Patent:
January 12, 2021
Assignee:
GALECTO BIOTECH AB
Inventors:
Fredrik Zetterberg, Ulf Nilsson, Hakon Leffler
Abstract: The invention relates to a compound of Formula I and methods of treating CFTR (cystic fibrosis transmembrane conductance regulator) mediated diseases, in particular cystic fibrosis, comprising the step of administering a therapeutically effective amount of a compound of Formula I to a patient in need thereof:
Abstract: The invention relates to a method for stabilising or reducing insulin resistance in patients having an obesity-related, metabolic disorder, the method comprising administering to the patient an effective amount of one or more human milk oligosaccharides (HMOs).
Type:
Grant
Filed:
June 15, 2016
Date of Patent:
January 5, 2021
Assignee:
GLYCOM A/S
Inventors:
Bruce McConnell, Louise Kristine Vigsnæs, Emma Elison
Abstract: The present invention relates to an immunity enhancing composition including an immune response modulator having a novel structure and, more specifically, to an immunity enhancing composition and a use of the same, wherein the immunity enhancing composition includes a lipopolysaccharide (LPS) analogue with reduced toxicity, and a cationic liposome. The present invention overcomes the physicochemical instability of a liposome, is advantageous in terms of production, transportation, and storage, and improves stability, thus being beneficial as an immune delivery system. In addition, the present invention includes an immune response modulator, and a cationic liposome, and thus exhibits an enhanced immunity-improving effect compared to the case in which an immune response modulator is used alone.
Type:
Grant
Filed:
October 30, 2017
Date of Patent:
December 29, 2020
Assignee:
EYEGENE INC.
Inventors:
Yang Je Cho, Kwangsung Kim, Na Gyong Lee, Shin Ae Park
Abstract: The present invention relates to a composition comprising a pharmaceutically acceptable carrier, at least one compound of the avermectin family, and at least one non-steroidal anti-inflammatory compound. The present invention further provides such composition for use in the treatment and/or the prevention of rosacea.
Type:
Grant
Filed:
August 4, 2017
Date of Patent:
December 29, 2020
Assignee:
NESTLÉ SKIN HEALTH SA
Inventors:
Jean Jacovella, Olivier Roye, André Jomard
Abstract: Compositions and method are therefore disclosed for treating ARDS. In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol (CDP-DAG) in a pharmaceutically acceptable carrier for use in treating ARDS.
Abstract: A SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, a SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal.
Type:
Grant
Filed:
November 28, 2016
Date of Patent:
December 15, 2020
Inventors:
Dania Birte Reiche, Laura Johnston, Nicole Mohren
Abstract: The present invention relates to a synthetic saccharide of general formula (I) that is related to Streptococcus pneumoniae serotype 2 capsular polysaccharide, a conjugate thereof and the use of said saccharide and conjugate for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae type 2 bacteria.
Type:
Grant
Filed:
December 16, 2016
Date of Patent:
December 15, 2020
Assignee:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
Inventors:
Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Naeem Khan, Madhu Emmadi
Abstract: A hydrocolloid or aqueous solution comprising a poly alpha-1,3-glucan ether compound is disclosed having a viscosity of at least about 10 centipoise (cPs). The poly alpha-1,3-glucan ether compound in these compositions has a degree of substitution of about 0.05 to about 3.0. Also disclosed is a method for increasing the viscosity of a hydrocolloid or aqueous composition using a poly alpha-1,3-glucan ether compound.
Type:
Grant
Filed:
June 13, 2018
Date of Patent:
December 15, 2020
Assignee:
DUPONT INDUSTRIAL BIOSCIENCES USA, LLC
Inventors:
Rahul B. Kasat, Jayme L. Paullin, Andrea M. Perticone, T. Joseph Dennes, Rakesh Nambiar, Michael W. Cobb
Abstract: A surfactant composition comprises at least one alkylglycoside having the formula CnGm wherein C is an alkyl group that is unbranched or branched, saturated or unsaturated, derivatised or non-derivatised, and n is the number of carbon atoms in the alkyl group and is 14 to 24. G is a saccharide residue containing 5 to 6 carbon atoms, and m is a number from 4 to 20. The use and application of the surfactant composition in detergents, emulsifying agents, wetting agents, anti-aggregation and stabilising composition and dispersants comprising the same is also disclosed.
Abstract: This invention relates to a method and composition for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation.
Type:
Grant
Filed:
February 24, 2017
Date of Patent:
December 8, 2020
Assignee:
GLYCOM A/S
Inventors:
Bruce McConnell, Louise Kristine Vigsnæs